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Abstract We characterized the recombinant glucuronyltrans-
ferase I (GlcAT-I) involved in the glycosaminoglycan-protein
linkage region biosynthesis. The enzyme showed strict specificity
for GalL1-3GalL1-4Xyl, exhibiting negligible incorporation into
other galactoside substrates including GalL1-3GalL1-O-benzyl,
GalL1-4GlcNAc and GalL1-4Glc. A comparison of the GlcAT-I
with another L1,3-glucuronyltransferase involved in the HNK-1
epitope biosynthesis revealed that the two L1,3-glucuronyltrans-
ferases exhibited distinct and no overlapping acceptor substrate
specificities in vitro. Nevertheless, the transfection of the GlcAT-
I cDNA into COS-1 cells induced the significant expression of
the HNK-1 epitope. These results suggested that the high
expression of the GlcAT-I gene rendered the cells capable of
synthesizing the HNK-1 epitope.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Proteoglycans are polyanionic molecules that are distrib-
uted on the surfaces of most cells and the extracellular ma-
trices in virtually every tissue, and comprise a wide range of
structures involving di¡erent core proteins and di¡erent
classes, numbers, and lengths of sulfated glycosaminoglycans
(GAGs) (for reviews, see [1,2]). Despite the ubiquity of this
family of molecules, a wide variety of proteoglycans with
characteristic sulfated GAG chains exhibit tissue-speci¢c and
developmentally regulated expression (for a review, see [3]),
and have been implicated in the regulation and maintenance
of cell proliferation, cytodi¡erentiation, and tissue morpho-
genesis (for a review, see [4]).
Sulfated GAGs including heparin/heparan sulfate, chon-
droitin sulfate and dermatan sulfate are covalently bound to
Ser residues in the core proteins through the common carbo-
hydrate-protein linkage structure, GlcAL1-3GalL1-3GalL1-
4XylL1-O-Ser [1,2]. The linkage region synthesis is initiated
by the addition of Xyl to speci¢c Ser residues in the core
protein followed by the addition of two Gal residues, and is
completed by the addition of a GlcA residue. GAGs are built
up on this linkage region by the alternating addition of N-
acetylhexosamine and GlcA residues. Heparin/heparan sulfate
is synthesized once GlcNAc is transferred to the common
linkage region, while chondroitin sulfate is formed if GalNAc
is ¢rst added. The addition of each sugar is thought to be
catalyzed by a speci¢c glycosyltransferase, which uses the cor-
responding UDP-sugar as a donor substrate [1,2].
The glucuronyl transfer to the Gal residue, the ¢nal biosyn-
thetic step of the common linkage region, is catalyzed by a
key enzyme, L1,3-glucuronyltransferase, that has been termed
glucuronyltransferase I (GlcAT-I). We recently cloned the
cDNA encoding the GlcAT-I from human placenta [5] based
upon the information of the amino acid sequence alignment of
rat glucuronyltransferase (GlcAT-P) involved in the biosyn-
thesis of the carbohydrate epitope HNK-1 with putative pro-
teins in Caenorhabditis elegans and Schistosoma mansoni [6].
The properties of GlcAT-I have not yet been described in
detail since attempts to purify GlcAT-I to homogeneity have
not been successful due to the low concentrations and the
di⁄culty in solubilizing the enzyme. In the present study,
the properties and substrate speci¢cities of the recombinant
GlcAT-I were determined and compared with those of the
recombinant GlcAT-P.
2. Materials and methods
2.1. Materials
UDP-[U-14C]GlcA (285.2 mCi/mmol) and unlabeled UDP-GlcA
were purchased from New England Nuclear (Boston, MA, USA)
and Sigma (St. Louis, MO, USA), respectively. Recombinant N-gly-
canase (N-glycosidase F; EC 3.5.1.52) was obtained from Boehringer
Mannheim (Mannheim, Germany). Chondroitin (a chemically desul-
fated derivative of whale cartilage chondroitin sulfate A), GalL1-4Glc,
GalL1-4GlcNAc, and the monoclonal antibody (HepSS-1) were pur-
chased from Seikagaku Corp. (Tokyo, Japan). GalL1-3GlcNAc and
GalL1-3GalNAc were obtained from Sigma. GalL1-3GalL1-4Xyl was
a kind gift from Dr. N.B. Schwartz (University of Chicago, Chicago,
IL, USA). GalL1-3GalL1-O-benzyl and GalL1-4GlcNAcL1-O-naph-
thalenemethanol [7] were kindly provided by Dr. J.D. Esko (Univer-
sity of California, San Diego, CA, USA).
2.2. Expression of the soluble forms of GlcAT-I and GlcAT-P and
enzyme assay
The construction of soluble forms of GlcAT-I and GlcAT-P fused
with the cleavable insulin signal sequence and the protein A IgG-
binding domain was carried out as described, respectively [5,6].
Each expression plasmid (10 Wg) was transfected into COS-1 cells
on 100-mm plates using LipofectAMINE (Life Technologies, Inc.,
Gaithersburg, MD, USA) according to the instructions provided by
the manufacturer. Two days after transfection, 1 ml of the culture
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medium was collected and incubated with 10 Wl of IgG-Sepharose
(Amersham Pharmacia Biotech, Uppsala, Sweden) for 1 h at 4‡C.
The beads recovered by centrifugation were washed with and then
resuspended in each assay bu¡er, and tested for glucuronyltransferase
activities using oligosaccharides (1 nmol each), chondroitin (300 Wg),
and asialoorosomucoid (20 Wg) as acceptor substrates as described,
respectively [8^10]. As shown in Section 3, the standard assay con-
ditions for GlcAT-I were established by examining various factors
such as bu¡ers, metal ions and substrate concentrations using
GalL1-3GalL1-4Xyl as an acceptor. The standard assay mixture con-
tained 10 Wl of the resuspended beads, 1 nmol of GalL1-3GalL1-4Xyl,
14.3 WM UDP-[14C]GlcA (1.66U105 dpm), 50 mM MES bu¡er, pH
6.5 and 2 mM MnCl2 in a total volume of 30 Wl. Reaction mixtures
were incubated at 37‡C for 4 h, and then 14C-labeled products were
separated from UDP-[14C]GlcA by passage of the reaction mixture
diluted in 1 ml 5 mM sodium phosphate, pH 6.8, through Pasteur
pipette columns containing Dowex 1-X8 (a PO234 form, 100^400
mesh: Bio-Rad, Tokyo, Japan). The isolated products were quanti¢ed
by scintillation spectrophotometry. The net [14C]GlcA incorporation
into GalL1-3GalL1-4Xyl was calculated by subtraction of the blank
value obtained in its absence. Under the established incubation con-
ditions for GlcAT-I, GlcA incorporation into GalL1-3GalL1-4Xyl was
proportional to the incubation period for up to 4 h (data not shown).
2.3. Immunoblotting
The puri¢ed GlcAT-I was digested with N-glycanase according to
the instructions provided by the manufacturer. After digestion, the
reaction mixture and the undigested sample were analyzed by 10%
SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to
a polyvinylidene di£uoride membrane (Bio-Rad). The membrane
was blocked with 20 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.05%
Tween-20 and 1% bovine serum albumin and then incubated with
the diluted antiserum (1:200) raised in rabbits against the motif IV
peptide EPRAANCTRVLVWHTRTEKP of the human GlcAT-I [5].
Bound antibodies were visualized with an enzyme reaction using al-
kaline phosphatase-conjugated goat anti-rabbit IgG (Promega, Mad-
ison, WI, USA) as a secondary antibody.
2.4. Construction of expression vector containing a full-length GlcAT-I
cDNA
The full-length GlcAT-I was ampli¢ed by polymerase chain reac-
tion (PCR) using a 5P-speci¢c primer (5P-GCTCTAGAGCGGCCAT-
GAAGCTGAA-3P) containing an XbaI site and the start codon and a
3P-speci¢c primer (5P-GCTCTAGAGCCTGAAAAGAGGTGGTAG-
3P) containing an XbaI site located 40 bp downstream of the stop
codon. PCR reactions were carried out with Pfu polymerase (Strata-
gene, La Jolla, CA, USA) with 30 cycles of a reaction consisting of
30 s of denaturation at 96‡C, 45 s of annealing at 60‡C, and 90 s of
elongation at 72‡C. The PCR fragment was subcloned into the XbaI
site of pEF-BOS [6].
2.5. Expression of the full-length GlcAT-I and GlcAT-P cDNAs in
COS-1 cells
COS-1 cells were seeded on tissue culture dishes (100 mm) and
transfected with 10 Wg of the full-length GlcAT-I cDNA in pEF-
BOS or the full-length GlcAT-P cDNA in pEF-BOS [6] using Lip-
ofectAMINE (Life Technologies) according to the instructions pro-
vided by the manufacturer. After 48 h, the COS-1 cells were washed
with phosphate-bu¡ered saline, scraped o¡ the dishes and homogen-
ized in 1.0 ml/dish of 50 mM MES bu¡er, pH 6.5 containing 1.0%
Triton X-100 and Complete (EDTA-free protease inhibitors; Boeh-
ringer Mannheim). The homogenates were used as the enzyme source.
For £uorescent immunostaining, the COS-1 cells were ¢xed with
methanol for 20 min at 320‡C, blocked with 3% bovine serum albu-
min for 30 min, incubated with 10 Wg/ml of the HNK-1 antibody [6]
or of HepSS-1 for 2 h at room temperature and then visualized with
£uorescein isothiocyanate (FITC)-conjugated anti-mouse IgM. These
cells were observed using a confocal laser scan microscope, Fluoview
(Olympus, Tokyo, Japan).
3. Results
3.1. Expression of a soluble form of the GlcAT-I
To facilitate the functional analysis of the glucuronyltrans-
ferase, a soluble form of the protein was generated by replac-
ing the ¢rst 43 amino acids of the glucuronyltransferase with a
cleavable insulin signal sequence and a protein A IgG-binding
domain as described [5], since the enzyme is tightly bound to
membranes [8]. When the expression plasmid containing the
GlcAT-I/protein A fusion was expressed in COS-1 cells, ap-
proximately 75-kDa and 65-kDa proteins were secreted (Fig.
1, lane 1). The apparent Mr of the 75-kDa fused protein was
reduced to 65 kDa after N-glycanase treatment (Fig. 1, lane
2), indicating that the one potential N-linked glycosylation site
of the GlcAT-I is partly being utilized. The fused enzyme
expressed in the medium was absorbed on IgG-Sepharose
beads to eliminate endogenous glucuronyltransferase, and
then the enzyme-bound beads were used as an enzyme source
for further studies.
3.2. Properties of the recombinant GlcAT-I activity
Fig. 2 shows the e¡ects of bu¡ers and pH on the recombi-
nant GlcAT-I. The activity was maximal at pH 6.5. The en-
zyme activity was somewhat a¡ected by the bu¡ers used. MES
bu¡er allowed over 1.4-fold more activity than HEPES bu¡er
at pH 6.5 (Fig. 2). Divalent cations were essential for the
enzymatic reaction, and 10 mM EDTA completely abolished
the activity (Fig. 3A). Mn2 exhibited the highest activity
under the standard assay conditions, and Mg2 and Cu2
were only 5.6 and 2.7% as e¡ective as Mn2, respectively
(Fig. 3A). The optimal concentration of Mn2 was about
2 mM (Fig. 3B).
To investigate the e¡ects of concentrations of the acceptor
GalL1-3GalL1-4Xyl and the donor UDP-GlcA, some of the
kinetic parameters of the GlcAT-I were determined. The ap-
parent Km values for GalL1-3GalL1-4Xyl and UDP-GlcA
were 80.4 WM and 29.3 WM, respectively (data not shown).
3.3. In vitro acceptor speci¢cities of the GlcAT-I and GlcAT-P
To distinguish the speci¢city of the GlcAT-I from that of
another L1,3-glucuronyltransferase, GlcAT-P, which has been
cloned, recombinant GlcAT-I was compared with the re-
combinant form of GlcAT-P for its utilization of a variety
Fig. 1. Expression of a soluble protein A/GlcAT-I fusion protein
and N-glycanase digestion of the fusion protein. Western blot of the
puri¢ed recombinant GlcAT-I (lane 1) and the N-glycanase digest
of the recombinant GlcAT-I (lane 2) separated by 10% SDS-PAGE
was incubated with the antiserum raised against the motif IV pep-
tide of the human GlcAT-I as described in Section 2.
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of acceptor substrates containing a terminal Gal or GalNAc
residue. An initial examination of GlcAT-I with oligosacchar-
ide substrates revealed that GalL1-3GalL1-4Xyl was the best
substrate and the apparent Km value for the acceptor sub-
strate was 80.4 WM as described above. Accordingly, we de-
cided to compare the speci¢cities of the two enzymes at a ¢xed
concentration of 33 WM for various acceptor substrates. As
shown in Table 1, the GlcAT-I utilized only GalL1-3GalL1-
4Xyl, and little incorporation was observed with other sub-
strates containing a terminal GalNAc or Gal residue, i.e. pol-
ymer chondroitin, N-acetyllactosamine, lactose, asialooroso-
mucoid, GalL1-3GlcNAc, GalL1-3GalNAc and notably
GalL1-3GalL1-O-benzyl. These ¢ndings indicated that the
minimum structural requirement for the acceptor substrate
of the GlcAT-I was the trisaccharide sequence GalL1-
3GalL1-4Xyl, and the enzyme recognized up to the third sac-
charide residue (Xyl) from the non-reducing end. In contrast,
the GlcAT-P preferentially utilized substrates containing the
terminal GalL1-4GlcNAc structure, i.e. GalL1-4GlcNAcL1-O-
naphthalenemethanol, N-acetyllactosamine and asialooroso-
mucoid, whereas little incorporation was observed with other
substrates, i.e. chondroitin, GalL1-3GalL1-4Xyl, GalL1-
3GlcNAc, GalL1-3GalNAc and remarkably, lactose. These
¢ndings indicated that the minimum structural requirement
for the acceptor substrate of the GlcAT-P was the disacchar-
ide sequence GalL1-4GlcNAc, and the enzyme recognized the
N-acetyl group of the GlcNAc residue. These results together
indicate that the substrate speci¢city of the GlcAT-I is clearly
distinct from that of the GlcAT-P in vitro.
3.4. Transfection of the full-length GlcAT-I cDNA into COS-1
cells
In view of the fact that the transfection of the full-length
GlcAT-P cDNA into COS-1 cells induced the expression of
the HNK-1 epitope [6], it was of interest to determine whether
the GlcAT-I cDNA transfectant induces the expression of the
HNK-1 epitope. Thus, the full-length GlcAT-I cDNA was
transfected into COS-1 cells to test the substrate speci¢city
of the intracellular GlcAT-I. As a control, the expression of
heparan sulfate was examined using the anti-heparan sulfate
monoclonal antibody HepSS-1. The expression levels of hep-
aran sulfate of both GlcAT-I and GlcAT-P transfectant were
comparable to that of the mock-transfected cells (Fig. 4A^C).
Unexpectedly, the transfection of the GlcAT-I cDNA into
COS-1 cells induced a signi¢cant expression of the HNK-1
epitope, although the intensity was somewhat weaker than
that of the GlcAT-P transfectant, as demonstrated by £uores-
cent immunostaining using an HNK-1 antibody followed by
an FITC-conjugated secondary antibody (Fig. 4E and F). In
contrast, the mock-transfected cells were not stained at all
under the conditions used (Fig. 4D), although the cells indeed
exhibited the endogenous GlcAT-I gene expression and
GlcAT-I activity (Table 2). To exclude the possibility that
the full-length membrane-bound forms of GlcAT-I and
Fig. 2. E¡ects of bu¡ers and pH on the activity of GlcAT-I. The ef-
fects of pH on the GlcA transfer to GalL1-3GalL1-4Xyl were deter-
mined under standard assay conditions with di¡erent bu¡ers at a ¢-
nal concentration of 50 mM. The bu¡ers were sodium acetate (a),
MES-NaOH (b), HEPES-NaOH (E), and Tris-HCl (F). Assays pro-
ceeded as described in Section 2. Data represent one of two series
of independent experiments, where the two series of experiments
gave essentially identical results.
Fig. 3. E¡ects of divalent cations and Mn2 concentration on the
GlcAT-I activity. A: The e¡ects of divalent cations on the GlcA
transfer to GalL1-3GalL1-4Xyl were determined under standard as-
say conditions with di¡erent divalent cations or EDTA at a ¢nal
concentration of 10 mM. B: The e¡ects of Mn2 concentrations on
the GlcA transfer to GalL1-3GalL1-4Xyl were determined under
standard assay conditions, except that the concentration of MnCl2
was varied. Assays proceeded as described in Section 2. Data repre-
sent one of two series of independent experiments, where the two
series of experiments gave essentially identical results.
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GlcAT-P show di¡erent substrate speci¢cities from those of
their soluble forms that lack both the cytoplasmic and the
transmembrane domains, the extracts of the full-length
GlcAT-I and GlcAT-P cDNA-transfected cells were assayed
for glucuronyltransferase activity using various acceptor sub-
strates. As shown in Table 2, the GlcAT-I and GlcAT-P
transfectants surely overexpressed the GlcAT-I and GlcAT-P
activities, respectively, and the substrate speci¢cities of the
expressed activities in these two full-length transfectants
were virtually identical to those of the corresponding soluble
forms (see Table 1). Therefore, these results altogether sug-
gested that the high expression of the GlcAT-I gene seemed to
render the cells capable of synthesizing the HNK-1 epitope by
an as yet unde¢ned mechanism.
4. Discussion
GlcAT-I activity was ¢rst detected in an embryonic chick
cartilage extract [8] and was subsequently partially puri¢ed
from embryonic chick brain [11] and mouse mastocytoma
cells [12]. However, attempts to purify GlcAT-I to homoge-
neity have not been successful due to the low concentrations
and the di⁄culty in solubilizing the enzyme. In this study, we
investigated the properties of recombinant GlcAT-I, which
was expressed in COS-1 cells as a soluble protein A chimeric
form and puri¢ed using IgG-Sepharose, and the substrate
speci¢city of the puri¢ed GlcAT-I was compared with that
of recombinant puri¢ed GlcAT-P. Our characterization of
the puri¢ed recombinant GlcAT-I revealed an Mn2 require-
ment for maximal activity and a pH optimum at pH 6.5,
basically in accordance with the results obtained using a par-
ticulate fraction prepared from embryonic chick cartilage as
an enzyme source [8]. However, in contrast to the previous
¢ndings that the reaction occurred over a wide pH range with
a poorly de¢ned maximum at pH 5.4 and reached a saturation
level at 15 mM Mn2 [8], the recombinant GlcAT-I exhibited
a relatively sharp maximum at pH 6.5, although the enzyme
activity was somewhat a¡ected by the bu¡ers used (Fig. 2)
and the reaction was stimulated by Mn2 up to 2 mM and
decreased at higher levels (Fig. 3B). In addition, the Km value
of the recombinant enzyme for UDP-GlcA was low (29.3 WM)
compared with the value (100 WM) of the chick cartilage en-
Fig. 4. Immuno£uorescence staining of transfected COS-1 cells by HepSS-1 and HNK-1 antibodies. COS-1 cells were transfected with the pEF-
BOS (A and D), the GlcAT-I cDNA in pEF-BOS (B and E) and the GlcAT-P cDNA in pEF-BOS (C and F), respectively, as described in Sec-
tion 2. Indirect immuno£uorescence staining of HepSS-1 (A^C) and HNK-1 epitopes (D^F). Scale bar, 200 Wm.
Table 1
Comparison of the acceptor speci¢city of GlcAT-I and GlcAT-P secreted into the culture medium by transfected COS-1 cells
Acceptor Enzyme activityb
GlcAT-I (pmol/ml medium/h) GlcAT-P (pmol/ml medium/h)
GalL1-3GalL1-4Xyl 14.2 0.5
GalL1-3GalL1-O-benzyl n.d.c n.d.
Chondroitin (GalNAcL1-4GlcA)n n.d. 1.2
Lactose (GalL1-4Glc) n.d. n.d.
N-Acetyllactosamine (GalL1-4GlcNAc) n.d. 14.9
Asialoorosomucoid (GalL1-4GlcNAc-R)a n.d. 71.6
GalL1-4GlcNAcL1-O-naphthalenemethanol n.d. 83.3
GalL1-3GlcNAc n.d. n.d.
GalL1-3GalNAc 0.2 n.d.
aR represents the remainder of the N-linked oligosaccharide chain.
bThe values represent the averages of two independent experiments.
cn.d., not detected (6 0.1 pmol/ml medium/h).
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zyme, although GalL1-3Gal was used as an acceptor in that
study [8] instead of GalL1-3GalL1-4Xyl.
Our previous characterization of the acceptor substrate spe-
ci¢city of recombinant GlcAT-I revealed that the enzyme
showed a strict speci¢city toward the linkage trisaccharide-
serine, GalL1-3GalL1-4XylL1-O-Ser [5]. Neither longer link-
age oligosaccharide-serines nor polymer chondroitin was uti-
lized as an acceptor substrate. These ¢ndings clearly indicate
that the transfer of GlcA to the linkage trisaccharide primer is
mediated by GlcAT-I, distinct from the enzyme that has been
termed glucuronyltransferase II involved in the formation of
the repeating disaccharide units of chondroitin sulfate, as pro-
posed previously [8,13]. Helting and Rode¤n [8] reported that
linkage region oligosaccharides such as GalL1-3Gal and
GalL1-3GalL1-4Xyl as well as GalL1-3GalL1-4XylL1-O-Ser
were good acceptors for GlcAT-I in a particulate enzyme
system prepared from embryonic chick cartilage. In fact, the
recombinant GlcAT-I e⁄ciently utilized GalL1-3GalL1-4Xyl
as an acceptor (the Km value was 80.4 WM), consistent with
the property of the previously characterized enzyme and with
the ¢nding that the serine residue is not essential for the GlcA
transfer. However, in contrast to the previous ¢ndings that
the disaccharide GalL1-3Gal was a good acceptor [8,12], the
recombinant GlcAT-I did not utilize GalL1-3GalL1-O-benzyl
linked to an arti¢cial aglycon as an acceptor under our assay
conditions (Table 1), indicating that the enzyme recognized up
to the third saccharide residue (Xyl) from the non-reducing
end. The trisaccharide recognition deduced from the present
study argues against the recent report by Wei et al. [14] who
described that GalL1-3GalL1-O-naphthalenemethanol and
GalL1-3GalL1-O-benzyl served as acceptors for the recombi-
nant hamster GlcAT-I which they obtained by expression
cloning.
The crude enzyme preparations including the embryonic
chick cartilage particulate fraction were shown to catalyze
the GlcA transfer not only to GAG-protein linkage region
fragments containing the characteristic structure (e.g. GalL1-
3GalL1-4Xyl) but also to disaccharides with analogous struc-
tures such as lactose (GalL1-4Glc) and N-acetyllactosamine
(GalL1-4GlcNAc) [8,11,12]. In strong contrast, neither lactose
nor N-acetyllactosamine was utilized by the recombinant en-
zyme in the present study (Table 1). Curenton et al. [15] sug-
gested that these glucuronyl transfer reactions might be cata-
lyzed by two distinct L1,3-glucuronyltransferases, GlcAT-I
and GlcAT-P. This hypothesis was in part con¢rmed by the
present characterization of these two recombinant enzymes.
However, considering the present ¢nding that neither the
recombinant GlcAT-I nor GlcAT-P transferred GlcA to lac-
tose, it is likely that a third member of the L1,3-glucuronyl-
transferase family that utilizes lactose as an acceptor substrate
exists.
In this study, we demonstrated that GlcAT-I and GlcAT-P
exhibited distinct and no overlapping acceptor substrate spe-
ci¢cities in vitro. Nevertheless, the transfection of GlcAT-I
cDNA into COS-1 cells induced the expression of the
HNK-1 epitope, although the intensity was somewhat weaker
than that of the GlcAT-P transfectant (Fig. 4). Although the
seeming discrepancy between the in vitro and in vivo substrate
speci¢cities remains to be clari¢ed, similar phenomena were
observed for other glycosyltransferases including sialyltrans-
ferases (for a review, see [16]). When vectors are used under
the control of a strong promoter to express an exogenous
cDNA, a signi¢cant amount of the protein is occasionally
expressed in the cells [16]. If a large amount of an enzyme
is expressed in the Golgi apparatus, a negligible in vitro ac-
tivity may become meaningful. On the basis of these results,
an incorrect conclusion may be drawn. In the present case,
considering that the mock-transfected cells were not stained at
all with the HNK-1 antibody although the cells indeed exhib-
ited the endogenous GlcAT-I gene expression and GlcAT-I
activity (Table 2), it is reasonable to speculate that the
GlcAT-I does not participate in the formation of the HNK-
1 epitope under physiological conditions. In fact, the GlcAT-I
gene is weakly, but ubiquitously expressed in virtually every
human tissue examined (Y. Tone, H. Kitagawa, and K. Su-
gahara, unpublished results), which is in accordance with the
observations that proteoglycans are distributed on the surfa-
ces of most cells and the extracellular matrices in virtually
every tissue [1,2], but in contrast to the ¢ndings that the ex-
pression of the HNK-1 epitope is highly restricted and is
temporally and spatially regulated during the development
of the nervous system [17]. Therefore, GlcAT-I seems to be
mainly involved in the biosynthesis of the GAG-protein link-
age region of proteoglycans. However, based on the present
¢ndings that the transfection of GlcAT-I cDNA into COS-1
cells induced a signi¢cant expression of the HNK-1 epitope, it
is possible that tissues which abundantly express the GlcAT-I
gene synthesize the HNK-1 epitope GlcA(3-O-sulfate)L1-
3GalL1-4GlcNAc, especially since the HNK-1 3-O-sulfotrans-
ferase is widely distributed in various tissues and GlcAT-P
most likely regulates the expression of the HNK-1 epitope
[18,19]. In accordance with this suggestion, Wei et al. recently
reported the expression of the HNK-1 epitope in GlcAT-I
cDNA-transfected COS-7 and Lec 2 cells when cotransfected
with the HNK-1 3-O-sulfotransferase [14]. Thus, in the cases
of some speci¢c developmental stages or under pathological
conditions including cancers, GlcAT-I may participate in the
synthesis of the HNK-1 epitope. In addition, considering that
Table 2
Comparison of the acceptor speci¢city of GlcAT-I and GlcAT-P in transfected COS-1 cells
Acceptor Enzyme activityb
Mock (pmol/mg protein/h) GlcAT-I (pmol/mg protein/h) GlcAT-P (pmol/mg protein/h)
GalL1-3GalL1-4Xyl 57.7 743.7 53.7
N-Acetyllactosamine (GalL1-4GlcNAc) n.d.c n.d. 76.4
Asialoorosomucoid (GalL1-4GlcNAc-R)a n.d. n.d. 765.9
GalL1-3GlcNAc n.d. n.d. n.d.
GalL1-3GalNAc n.d. 2.5 n.d.
aR represents the remainder of the N-linked oligosaccharide chain.
bThe values represent the averages of two independent experiments.
cn.d., not detected (6 0.5 pmol/mg protein/h).
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the GlcAT-I cDNA-transfected COS-1 cells did not express
any GlcAT-P activity using both asialoorosomucoid or N-ace-
tyllactosamine in spite of the fact that the GlcAT-I cDNA-
transfected cells exhibited over 10-fold higher expression of
GlcAT-I activity than that of the mock-transfected cells (Ta-
ble 2), the possibility that COS-1 cells contain an as yet un-
identi¢ed acceptor substrate for GlcAT-I to form the HNK-1
epitope can not be ruled out. In future studies, it is necessary
to determine the carbohydrate structure of the HNK-1 anti-
body-reactive product in COS-1 cells transfected with GlcAT-
I cDNA.
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